The combination of ceritinib and enzalutamide showed a robust inhibitory effect on cell growth of AR+ TNBC cells in vitro and in vivo….The combination of paclitaxel and ceritinib showed drastic inhibition of tumor growth compared to a single drug alone....All agents used in our study are FDA-approved, and thus the proposed combination therapy will likely be useful in the clinic.